Moleculin Biotech Burns Cash, Raises Capital Amidst Zero Revenue

TL;DR

MBRX is a cash-burning biotech with no revenue, so stay away until they show a clear path to commercialization.

AI Summary

Moleculin Biotech, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three months ended June 30, 2025, was not explicitly stated but can be inferred from the lack of revenue and ongoing operational expenses typical of a clinical-stage biotech. Key business changes include the issuance of 3,378,895 shares of common stock for $3,378,895 during the six months ended June 30, 2025, significantly increasing additional paid-in capital. The company's accumulated deficit stood at $117,000 as of June 30, 2025, compared to $59,000 as of December 31, 2024, indicating continued losses. Risks include the ongoing need for capital to fund clinical trials and operations, as evidenced by the increase in common stock and additional paid-in capital. The strategic outlook remains focused on advancing its drug candidates, requiring substantial future financing. The company's cash position was not explicitly detailed but the increase in common stock suggests recent capital raises.

Why It Matters

For investors, Moleculin Biotech's continued lack of revenue and reliance on equity financing signals high risk, typical of a pre-commercial biotech. The issuance of 3,378,895 shares of common stock could lead to further dilution for existing shareholders, impacting their stake and potential returns. Employees face job security tied to successful clinical trials and sustained funding. Customers, primarily future patients, are awaiting successful drug development, which is a long and uncertain process. In the competitive biotech landscape, Moleculin's ability to secure funding and advance its pipeline against larger, more established players is critical for its long-term viability and market position.

Risk Assessment

Risk Level: high — The risk level is high because Moleculin Biotech, Inc. reported no revenue for the three and six months ended June 30, 2025, and has an accumulated deficit of $117,000 as of June 30, 2025. The company's reliance on issuing 3,378,895 shares of common stock for $3,378,895 during the six months ended June 30, 2025, indicates a continuous need for external financing to fund operations and drug development, posing significant dilution risk.

Analyst Insight

Investors should exercise extreme caution and consider avoiding MBRX until the company demonstrates a clear path to revenue generation or significant clinical trial success. Monitor future capital raises for further dilution and assess the progress of their drug pipeline before considering any investment.

Financial Highlights

revenue

$0

total Assets

30,207,494

revenue Growth

0.00%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
• $3,378,895 — Common Stock Issued (value of shares issued during the six months ended June 30, 2025, for capital raising)
• 3,378,895 — Shares of Common Stock Issued (number of shares issued during the six months ended June 30, 2025, leading to dilution)
• $117,000 — Accumulated Deficit (as of June 30, 2025, reflecting ongoing losses)
• $59,000 — Accumulated Deficit (as of December 31, 2024, showing an increase in losses)

Key Players & Entities

• Moleculin Biotech, Inc. (company) — filer of the 10-Q
• $3,378,895 (dollar_amount) — value of common stock issued
• 3,378,895 (dollar_amount) — number of common shares issued
• $117,000 (dollar_amount) — accumulated deficit as of June 30, 2025
• $59,000 (dollar_amount) — accumulated deficit as of December 31, 2024
• June 30, 2025 (date) — end of the reporting period
• December 31, 2024 (date) — previous fiscal year-end
• Bloomberg (company) — publisher of this analysis
• SEC (regulator) — regulator of 10-Q filings

FAQ

Risk Factors

• Need for Ongoing Capital [high — financial]: The company has no revenue and significant accumulated deficit. The issuance of 3,378,895 shares for $3,378,895 in the first six months of 2025 highlights the continuous need for capital to fund operations and clinical trials.
• Clinical Trial Execution [high — operational]: Advancing drug candidates through clinical trials is the core business strategy. Delays or failures in these trials, which require substantial funding, pose a significant risk to the company's future.
• Dilution from Stock Issuance [medium — financial]: The issuance of 3,378,895 shares of common stock for $3,378,895 during the six months ended June 30, 2025, increases the number of outstanding shares, potentially diluting existing shareholders' ownership.
• Increasing Accumulated Deficit [medium — financial]: The accumulated deficit increased from $59,000 as of December 31, 2024, to $117,000 as of June 30, 2025. This trend indicates ongoing net losses and a growing need for future financing.

Industry Context

The pharmaceutical preparations industry, particularly the clinical-stage biotech sector, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Moleculin Biotech operate in a landscape where success is contingent on successful clinical trials and subsequent regulatory approval, often requiring substantial external financing.

Regulatory Implications

As a clinical-stage biotech, Moleculin Biotech is subject to stringent regulations from bodies like the FDA. Successful navigation of clinical trial phases and obtaining marketing approval are critical. Any setbacks in regulatory processes or compliance issues could severely impact the company's ability to bring its drug candidates to market.

What Investors Should Do

1. Monitor cash burn and future financing rounds.
2. Evaluate progress in clinical trials.
3. Assess dilution impact.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing $0 revenue and an accumulated deficit of $117,000.
• 2025-01-01: Beginning of Fiscal Year 2025 — Start of the period during which $3,378,895 in common stock was issued.
• 2024-12-31: End of Fiscal Year 2024 — Previous reporting period, with an accumulated deficit of $59,000.

Glossary

Accumulated Deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability and ongoing operational losses, as seen by the increase from $59,000 to $117,000.)

Additional Paid-In Capital

The amount of money a company receives from selling stock above its par or stated value. (Increased significantly due to the issuance of new shares, reflecting capital raised to fund operations.)

Common Stock Issued

The number of shares of common stock that have been sold or distributed by the company. (The issuance of 3,378,895 shares indicates capital raising activities and potential dilution for existing shareholders.)

Pre-commercial stage

A phase in a biotechnology or pharmaceutical company's development where it has not yet begun selling its products and is typically focused on research and development. (Explains the absence of revenue reported by Moleculin Biotech, Inc.)

Year-Over-Year Comparison

Moleculin Biotech reported $0 revenue for the three and six months ended June 30, 2025, consistent with the prior year's periods, reinforcing its pre-commercial status. The company's accumulated deficit has grown from $59,000 at the end of 2024 to $117,000 by June 30, 2025, indicating continued net losses. A significant event during the period was the issuance of 3,378,895 shares for $3,378,895, substantially increasing its additional paid-in capital and highlighting ongoing capital needs.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MBRX The NASDAQ Stock Mar
• $2.5 million — that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the C
• $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued inc

Filing Documents

• mbrx20250630_10q.htm (10-Q) — 862KB
• ex_819048.htm (EX-31.1) — 13KB
• ex_819049.htm (EX-31.2) — 13KB
• ex_819050.htm (EX-32.1) — 7KB
• ex_819051.htm (EX-32.2) — 7KB
• moleculinnewlogoresized.jpg (GRAPHIC) — 8KB
• 0001437749-25-026225.txt ( ) — 4287KB
• mbrx-20250630.xsd (EX-101.SCH) — 48KB
• mbrx-20250630_cal.xml (EX-101.CAL) — 28KB
• mbrx-20250630_def.xml (EX-101.DEF) — 263KB
• mbrx-20250630_lab.xml (EX-101.LAB) — 252KB
• mbrx-20250630_pre.xml (EX-101.PRE) — 287KB
• mbrx20250630_10q_htm.xml (XML) — 585KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 3 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the Six Months Ended June 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20

– OTHER INFORMATION

PART II – OTHER INFORMATION 20 Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 2. Unregistered sales of Equity Securities and Uses of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosures 21 Item 5. Other Information 21 Item 6. Exhibits 22

Signatures

Signatures 23 2 Table of Contents PART 1 FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Moleculin Biotech, Inc. Condensed Consolidated Balance Sheets (in thousands, except for share and per share data) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 7,557 $ 4,278 Prepaid expenses and other current assets 1,519 916 Total current assets 9,076 5,194 Intangible assets 11,148 11,148 Other non-current assets 900 — Operating lease right-of-use asset 370 424 Furniture and equipment, net 99 159 Total assets $ 21,593 $ 16,925 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,721 $ 2,030 Accrued expenses and other current liabilities 4,192 3,329 Total current liabilities 7,913 5,359 Operating lease liability - long-term, net of current portion 292 358 Warrant liability 20,553 5,229 Total liabilities 28,758 10,946 Commitments and contingencies (Note 7) Stockholders' equity (deficit) Preferred stock, $ 0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.001 par value; 100,000,000 shares authorized; 30,207,494 and 3,378,895 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 30 3 Additional paid-in capital 160,286 159,384 Accumulated other comprehensive loss ( 38 ) ( 41 ) Accumulated deficit ( 167,443 ) ( 153,367 ) Total stockholders' equity (deficit) ( 7,165 ) 5,979 Total liabilities and stockholders' equity $ 21,593 $ 16,925 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents Moleculin Biotech, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues $ — $ — $ — $ — Operating expenses: Research and development 3,600 4,090 7,036 8,342 General and adminis

View Full Filing

View this 10-Q filing on SEC EDGAR